Sections View Full Chapter Figures Tables Videos Annotate Full Chapter Figures Tables Videos Supplementary Content +++ Abbreviations ++Table Graphic Jump Location|Download (.pdf)|PrintACSAcute coronary syndromeACLSAdvanced cardiovascular life supportCICardiac indexCVDCardiovascular diseaseCVPCentral venous pressureHRHeart rateICPIntracranial pressureIOIntraosseousMAPMean arterial pressurePEAPulseless electrical activityRASSRichmond agitation sedation scaleRSIRapid sequence intubationSBPSystolic blood pressureScvO2Central venous oxygen saturationSvO2Venous oxygen saturationVFVentricular fibrillationVTVentricular tachycardia++Table Graphic Jump LocationTable 12.1 Rapid Sequence IntubationView Table||Download (.pdf)Table 12.1 Rapid Sequence IntubationAgentDoseIndicationCommentsPretreatment (not routinely indicated)Lidocaine100 mgElevated ICPProtects from elevated ICPFentanyl2–3 μg/kgElevated ICP, CVDDecreases catecholamine surgeInductionEtomidate0.3 mg/kgEmergency RSIMay cause adrenal insufficiencyKetamine1.5 mg/kgRSI in patients septic or with reactive airwaysCaution in CVD and in hypertensive patients. May pretreat with atropinePropofol1.5 mg/kgRSI with reactive airway or status epilepticusNegative effects on CV system; bolus dosing may cause hypotensionMidazolam0.2–0.3 mg/kgAlternative for RSIVariable responseParalyticSuccinylcholine1.5 mg/kgAgent of choice for RSIAvoid in patients with hyperkalemiaRocuronium1 mg/kgRSI when succinylcholine contraindicatedDuration up to 60 min; activity prolonged in patients with hepatic failureVecuronium0.15 mg/kgUsed when succinylcholine and rocuronium not availableDuration up to 60 min; priming dose of 0.01 mg/kg give prior to RSI dose; activity prolonged in patients with renal and hepatic failure++Table Graphic Jump LocationTable 12.2.1 Sedation AgentsView Table||Download (.pdf)Table 12.2.1 Sedation AgentsAgentStarting DoseTitrationaCommentsPropofol5–20 μg/kg/min5 μg/kg/min Q 5 minMax rate 50 μg/kg/min (institutional dependant); adverse effects: hypotension, high lipid content (1.1 kcal/mL), myocardial depressant. Sulfites in some formulationsMidazolam1 mg/h1 mg/h Q 15 minCYP 3A4 interactions; benzyl alcohol in injectionLorazepam0.5 mg/h0.5–1 mg/h Q 15 minPropylene glycol and polyethylene glycol in injection. Reduce dose by 50% with concomitant valproic acid use. Use caution with renal and hepatic impairmentDexmedetomidine0.4 μg/kg/h0.1 μg/kg/h Q 15 minMax rate 0.7 μg/kg/h; dose-related bradycardia and hypotension; add adjunctive midazolam. FDA indicated for 24-h use; data available for 5-day useaTitration should be based on RASS.++Table Graphic Jump LocationTable 12.2.2 Opioid AgentsView Table||Download (.pdf)Table 12.2.2 Opioid AgentsAgentStarting DoseTitrationaCommentsMorphine1 mg/h1 mg/h Q 1 hProlonged activity in renal failure, hypotension, bronchospasmHydromorphone0.2 mg/h0.2 mg/h Q 1 hProlonged activity in renal and hepatic failure, hypotensionFentanyl25 μg/h25–50 μg/h Q 15 minNot prolonged in renal failure, chest wall rigidity with high-dose infusionsaTitration should be based on RASS and Pain Scale.++Table Graphic Jump LocationTable 12.2.3 Paralytic AgentsView Table||Download (.pdf)Table 12.2.3 Paralytic AgentsAgent... Your Access profile is currently affiliated with [InstitutionA] and is in the process of switching affiliations to [InstitutionB]. Please select how you would like to proceed. Keep the current affiliation with [InstitutionA] and continue with the Access profile sign in process Switch affiliation to [InstitutionB] and continue with the Access profile sign in process Get Free Access Through Your Institution Learn how to see if your library subscribes to McGraw Hill Medical products. Subscribe: Institutional or Individual Sign In Error: Incorrect UserName or Password Username Error: Please enter User Name Password Error: Please enter Password Sign in Forgot Password? Forgot Username? Download the Access App: iOS | Android Sign in via OpenAthens Sign in via Shibboleth You already have access! Please proceed to your institution's subscription. Create a free profile for additional features.